Supriya Lifescience Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Supriya Lifescience Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹274
Per ShareLot Size
54 Shares
Minimum Investment
₹14,796
Issue Size
₹700 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
10%
QIB Quota
75%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Supriya Lifescience Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
99.26%
Promoter Holding (Post-Issue)
67.58%
Issue Type
Book Building
ISIN
INE07RO01027
About the Company
Supriya Lifescience Limited is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients ("APIs"), with a focus on research and development. As of October 31, 2021, The company has niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. The company has consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between Fiscal 2017 and 2021. The company was among the largest exporters of Salbutamol Sulphate in India contributing to 31% of the API exports from India in FY 2021 in volume terms.
Industry Overview
The Indian pharmaceutical industry can be broadly classified into formulations and bulk drugs. Formulations can be further divided into domestic and export formulations. Bulk drugs can also be similarly categorised. About USD 3.9 billion worth of bulk drugs were exported in fiscal 2020. A major part is sold in the domestic market and also used for captive consumption with many large formulation players performing backward integration. Global pharmaceutical market has grown by around 4.8% CAGR from ~USD 955 billion in CY14 to ~USD 1,270 billion in CY20. It is expected to sustain this growth over the next five years to reach USD 1,585-1,625 billion in CY25. New product launches, widespread population aging and sedentary lifestyles leading to increased chronic disease prevalence, technological advances, new methods for drug discovery, and an increase in pharmaceutical drug usage have been some of the key growth drivers for the industry.
Company History
The Company was incorporated as "Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.
Products & Services
- The Company manufactures Active Pharmaceuticals Ingredients. Its focus is primarily on diverse therapeutic areas and niche products.
Growth Strategy
- Expansion of manufacturing capabilities
- Expanding product portfolio with increasing R&D capabilities
- Increase current market presence and enter new markets
- Continue to focus on operational excellence
Customer Base
Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of 25,547,445* equity shares of face value of Rs. 2 each ("Equity Shares") of Supriya Lifescience Limited ("The Company" or the "Issuer") for cash at a price of Rs. 274 per equity share ("Offer Price") aggregating to Rs. 700.00 crores, comprising a fresh issue of 7,299,270* equity shares aggregating to Rs. 200.00 crores ("Fresh Issue") and an offer for sale of 18,248,175* equity shares aggregating to Rs. 500.00 crores by Satish Waman Wagh (The "Promoter Selling Shareholder") (The "Offer for Sale", together with the fresh issue, the "Offer"). The offer will constitute 31.74% of the post-offer paid-up equity share capital. *Subject to finalisation of basis of allotment The face value of each equity share is Rs. 2 each. The offer price is 137 times the face value of the equity shares. Bids can be made for a minimum of 54 equity shares and in multiples of 54 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Significant scale with leadership position across key & niche products;
- Backward integrated business model;
- Advanced manufacturing and research and development capabilities;
- Consistent financial performance due to de-risked business model;
- Experienced senior management team and qualified operational personnel.
- The company's derive a significant portion of its revenue from the sale of certain products and any reduction in demand for these products could have an adverse effect on its business, results of operations and financial condition.
- The company derive a significant portion of its revenue from a few customers and the loss of one or more such customers, the deterioration of their financial condition or prospects, or a reduction in their demand for its products could adversely affect its business, results of operations and financial condition.
- Its international operations expose its to complex management, legal, tax and economic risks, which could adversely affect its business, results of operations and financial condition.
- If the company do not successfully develop or commercialise new products in a timely manner, or if the products that its commercialise do not perform as expected, its business, results of operations and financial condition may be adversely affected.
- The COVID-19 pandemic, or any future pandemic or widespread public health emergency, could materially and adversely impact its business, financial condition, cash flows and results of operations.